- Home
- RDW vs OCS Comparison
RDW vs OCS Comparison
Compare RDW & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDW
- OCS
- Stock Information
- Founded
- RDW 2020
- OCS 2003
- Country
- RDW United States
- OCS Switzerland
- Employees
- RDW N/A
- OCS N/A
- Industry
- RDW Military/Government/Technical
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- RDW Industrials
- OCS Health Care
- Exchange
- RDW Nasdaq
- OCS Nasdaq
- Market Cap
- RDW 987.6M
- OCS 1.0B
- IPO Year
- RDW N/A
- OCS N/A
- Fundamental
- Price
- RDW $6.00
- OCS $19.00
- Analyst Decision
- RDW Buy
- OCS Strong Buy
- Analyst Count
- RDW 6
- OCS 4
- Target Price
- RDW $15.00
- OCS $42.50
- AVG Volume (30 Days)
- RDW 6.4M
- OCS 104.4K
- Earning Date
- RDW 11-05-2025
- OCS 11-10-2025
- Dividend Yield
- RDW N/A
- OCS N/A
- EPS Growth
- RDW N/A
- OCS N/A
- EPS
- RDW N/A
- OCS N/A
- Revenue
- RDW $296,147,000.00
- OCS $991,999.00
- Revenue This Year
- RDW $34.83
- OCS $32.89
- Revenue Next Year
- RDW $41.86
- OCS $1,043.16
- P/E Ratio
- RDW N/A
- OCS N/A
- Revenue Growth
- RDW N/A
- OCS N/A
- 52 Week Low
- RDW $5.72
- OCS $14.00
- 52 Week High
- RDW $26.66
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- RDW 33.41
- OCS 40.86
- Support Level
- RDW $5.72
- OCS $19.02
- Resistance Level
- RDW $7.45
- OCS $19.68
- Average True Range (ATR)
- RDW 0.51
- OCS 0.73
- MACD
- RDW -0.14
- OCS -0.27
- Stochastic Oscillator
- RDW 9.24
- OCS 0.65
About RDW Redwire Corporation
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.